The Association between miR-146a Gene Polymorphism and Cervical Intraepithelial Neoplasia
-
摘要:
目的 探究miR-146a基因的单核苷酸多态性(single nucleotide polymorphisms,SNP)rs57095329、rs6864584与宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)的相关性。 方法 利用SPSS软件随机收集96例CIN患者作为CIN组,225名健康个体作为对照组,采用TaqMan探针法方法对以上SNP位点进行基因分型,分析其与CIN的相关性。 结果 rs57095329位点的等位基因和基因型分布相对于对照组差异具有统计学意义,CIN组中等位基因A的频率显著低于对照组(P < 0.001;OR = 0.48,95%CI:0.32~0.70);在显性模式下,携带G等位基因(A/G-G/G)的个体CIN发生风险显著升高(P < 0.001;OR = 2.67,95% CI:1.64~4.37)。但rs6864584位点与CIN的发生风险及组织学分期均无相关性。 结论 miR-146a基因rs57095329位点的A等位基因可能是CIN的保护性因素。 Abstract:Objective To investigate the association between single nucleotide polymorphisms (SNP) rs57095329 and rs6864584 of miR-146a gene and cervical intraepithelial neoplasia (CIN) in Yunnan Han population. Method A total of 96 patients diagnosed with CIN in the Third Affiliated Hospital of Kunming Medical University were randomly collected as the CIN group, and 225 healthy individuals examined during the same period were selected as the control group using SPSS software. Genotyping of the above SNP loci was performed using the TaqMan probe method. and their correlation with CIN was analyzed. Results The allele and genotype distribution of rs57095329 showed a statistically significant differences compared to the control group. with the frequency of the allele A in the CIN group significantly lower than that in the control group (P < 0.001; OR = 0.48, 95%CI: 0.32~0.70). In the dominant model, individuals carrying the G allele (A/G-G/G) had a significantly increased risk of CIN (P < 0.001; OR = 2.67, 95%CI: 1.64~4.37). In contrast, no correlation was found between the rs6864584 and the risk of CIN or histological staging (P > 0.016). Conclusion The A allele of the miR-146a gene at the rs57095329 locus may be a protective factor for CIN. -
表 1 SNP位点的等位基因和基因型在对照组和CIN组中的分布特征[n (%)]
Table 1. Distribution characteristics of allele and genotype at SNP loci in the control group and CIN group [n (%)]
SNPs 等位基因/基因型 对照组 CIN组 HWE 对照组 vs CIN组 χ2 P χ2 P OR (95%CI) rs57095329 A 370(82.2) 132(68.8) 0.742 0.389 14.325 < 0.001* 0.48[0.32~0.70] G 80(17.8) 60(31.2) A/A 154(68.4) 43(44.8) 15.888 < 0.001* A/G 62(27.6) 46(47.9) G/G 9(4.0) 7(7.3) rs6864584 C 38(8.4) 13(6.8) 0.116 0.733 0.515 0.473 0.79[0.41~1.51] T 412(91.6) 179(93.2) C/C 2(0.9) 0(0.0) 1.014 0.602 C/T 34(15.1) 13(13.5) T/T 189(84.0) 83(86.5) *P < 0.025。 表 2 SNP位点在对照组和CC、CIN中的遗传模式分析[n (%)]
Table 2. Genetic model analysis of SNP loci in the control,CC,and CIN groups [n (%)]
SNPs 模型 基因型 对照组
n (%)CIN组
n (%)对照组 vs CIN组 χ2 P OR (95%CI) rs57095329 共显性 A/A 154(68.4) 43 (44.8) 14.555 < 0.001 1.00 A/G 62 (27.6) 46 (47.9) 2.66(1.60~4.42) G/G 9 (4.0) 7 (7.3) 2.79(0.98~7.91) 显性 A/A 154(68.4) 43 (44.8) 15.879 < 0.001 1.00 A/G-G/G 71 (31.6) 53 (55.2) 2.67(1.64~4.37) 隐性 A/A-A/G 216(96.0) 89 (92.7) 1.539 0.230 1.00 G/G 9 (4.0) 7 (7.3) 1.89(0.68~5.23) 超显性 A/A-G/G 163(72.4) 50 (52.1) 12.496 < 0.001 1.00 A/G 62 (27.6) 46 (47.9) 2.42(1.47~3.97) 逻辑累加 --- --- --- 17.055 < 0.001 2.12(1.42~3.16) rs6864584 共显性 T/T 189(84.0) 83 (86.5) 0.155 0.450 1.00 T/C 34 (15.1) 13 (13.5) 0.87(0.44~1.73) C/C 2 (0.9) 0 (0.0) --- 显性 T/T 189(84.0) 83 (86.5) 0.314 0.570 1.00 T/C-C/C 36 (16.0) 13 (13.5) 0.82(0.41~1.63) 隐性 T/T-T/C 223(99.1) 96(100.0) 0.859 0.230 1.00 C/C 2 (0.9) 0 (0.0) --- 超显性 T/T-C/C 191(84.9) 83 (86.5) 0.133 0.710 1.00 T/C 34 (15.1) 13 (13.5) 0.88(0.44~1.75) 逻辑累加 --- --- --- 0.519 0.470 0.79(0.41~1.51) -
[1] Jemal A,Bray F,Center M M,et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90. doi: 10.3322/caac.20107 [2] Chen W,Zheng R,Baade P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132. doi: 10.3322/caac.21338 [3] De freitas A C,Gurgel A P,Chagas B S,et al. Susceptibility to cervical cancer: An overview[J]. Gynecol Oncol,2012,126(2):304-311. doi: 10.1016/j.ygyno.2012.03.047 [4] Zur hausen H. Papillomaviruses in the causation of human cancers-A brief historical account[J]. Virology,2009,384(2):260-265. doi: 10.1016/j.virol.2008.11.046 [5] Siegler E,Shiner M,Segev Y,et al. Prevalence and Genotype Distribution of HPV Types in Women at Risk for Cervical Neoplasia in Israel[J]. Isr Med Assoc J,2017,19(10):635-639. [6] Virolainen S J,Vonhandorf A,Viel K C M F,et al. Gene–environment interactions and their impact on human health[J]. Genes & Immunity,2023,24(1):1-11. [7] Crosbie E J,Einstein M H,Franceschi S,et al. Human papillomavirus and cervical cancer[J]. Lancet,2013,382(9895):889-899. doi: 10.1016/S0140-6736(13)60022-7 [8] Fang J,Li Y,Zhang J,et al. Correlation between polymorphisms in microRNA-regulated genes and cervical cancer susceptibility in a Xinjiang Uygur population[J]. Oncotarget,2017,8(19):31758-31764. doi: 10.18632/oncotarget.15970 [9] 李娅亨,杨希,杨佳,等. miR-155和miR-200b基因多态性与云南汉族人群宫颈癌及宫颈上皮内瘤变的相关性[J]. 贵阳医学院学报,2021,046(5):504-510. [10] 刘伟鹏,许金美,杨佳,等. miR-34a,miR-155及miR-486基因多态性与宫颈癌前病变和宫颈癌相关性研究[J]. 中华肿瘤防治杂志,2022,29(07):488-493. [11] Bartel D P. Metazoan MicroRNAs[J]. Cell,2018,173(1):20-51. doi: 10.1016/j.cell.2018.03.006 [12] 张云云. EGFL7和miR-126参与肺癌发生风险的遗传分析和功能研究 [D]. 北京协和医学院,2022. [13] Wang J Y,Chen L J. The role of miRNAs in the invasion and metastasis of cervical cancer[J]. Biosci Rep,2019,39(3):BSR20181377. doi: 10.1042/BSR20181377 [14] Jia H,Cao M,Hao S,et al. Prediction of prognosis,immune infiltration and immunotherapy response with N6-methyladenosine-related lncRNA clustering patterns in cervical cancer[J]. Scientific Reports,2022,12(1):17256. doi: 10.1038/s41598-022-20162-2 [15] Ma Q,Yu W,Li Z,et al. Circ_0081723 enhances cervical cancer progression and modulates CREBRF via sponging miR-545-3p[J]. Naunyn Schmiedebergs Arch Pharmacol,2024,397(11):8839-8852. doi: 10.1007/s00210-024-03175-8 [16] Gao W,Hua J,Jia Z,et al. Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells[J]. Oncol Lett,2018,15(6):9884-9888. [17] Sandhu R,Rein J,D'arcy M,et al. Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status[J]. Carcinogenesis,2014,35(11):2567-2575. doi: 10.1093/carcin/bgu175 [18] Yue C,Wang M,Ding B,et al. Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population[J]. Gynecol Oncol,2011,122(1):33-37. doi: 10.1016/j.ygyno.2011.03.032 [19] Pecorelli S. Revised FIGO staging for carcinoma of the vulva,cervix,and endometrium[J]. Int J Gynaecol Obstet,2009,105(2):103-104. doi: 10.1016/j.ijgo.2009.02.012 [20] Schiffman M,Castle P E,Jeronimo J,et al. Human papillomavirus and cervical cancer[J]. Lancet,2007,370(9590):890-907. doi: 10.1016/S0140-6736(07)61416-0 [21] 郭妮,张承,洪超,等. KRAS基因3'UTR多态性与云南汉族人群宫颈癌及宫颈上皮内瘤变的相关性[J]. 昆明医科大学学报,2024,45(2):14-22. doi: 10.12259/j.issn.2095-610X.S20240203 [22] 牛志鑫,汤丽华,史磊,等. MAPK1与NRAS基因多态性与云南汉族人群宫颈上皮内瘤变的相关性[J]. 昆明医科大学学报,2024,45(5):8-15. doi: 10.12259/j.issn.2095-610X.S20240502 [23] Shi Y Y,He L. SHEsis,a powerful software platform for analyses of linkage disequilibrium,haplotype construction,and genetic association at polymorphism loci[J]. Cell Res,2005,15(2):97-98. doi: 10.1038/sj.cr.7290272 [24] Hu Z,Zhu D,Wang W,et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism[J]. Nat Genet,2015,47(2):158-163. doi: 10.1038/ng.3178 [25] Zhou X,Chen X,Hu L,et al. Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer,a case-control study in Chinese women[J]. Gynecol Oncol,2010,117(2):287-290. doi: 10.1016/j.ygyno.2010.01.020 [26] Xie K,Chen M,Zhu M,et al. A polymorphism in miR-1262 regulatory region confers the risk of lung cancer in Chinese population[J]. Int J Cancer,2017,141(5):958-966. doi: 10.1002/ijc.30788 [27] Mir R,Al balawi I A,Duhier F M A. Involvement of microRNA-423 Gene Variability in Breast Cancer Progression in Saudi Arabia[J]. Asian Pac J Cancer Prev,2018,19(9):2581-2589. [28] Yan Z,Zhou Z,Li C,et al. Polymorphisms in miRNA genes play roles in the initiation and development of cervical cancer[J]. J Cancer,2019,10(20):4747-4753. doi: 10.7150/jca.33486 [29] Wu Y,Hao X,Feng Z,et al. Genetic polymorphisms in miRNAs and susceptibility to colorectal cancer[J]. Cell Biochem Biophys,2015,71(1):271-278. doi: 10.1007/s12013-014-0195-y [30] Liu H,Zhou Y,Liu Q,et al. Association of miR-608 rs4919510 polymorphism and cancer risk: a meta-analysis based on 13,664 subjects[J]. Oncotarget,2017,8(23):37023-37031. doi: 10.18632/oncotarget.9509 [31] Bastami M,Choupani J,Saadatian Z,et al. Evidences from a systematic review and meta-analysis unveil the role of miRNA polymorphisms in the predisposition to female neoplasms[J]. Int J Mol Sci,2019,20(20):5088. doi: 10.3390/ijms20205088 [32] Srivastava S,Singh S,Fatima N,et al. Pre-microRNA gene polymorphisms and risk of cervical squamous cell carcinoma[J]. J Clin Diagn Res,2017,11(9):GC01-GC04. [33] Min P,Li W,Zeng D,et al. A single nucleotide variant in microRNA-1269a promotes the occurrence and process of hepatocellular carcinoma by targeting to oncogenes SPATS2L and LRP6[J]. Bull Cancer,2017,104(4):311-320. doi: 10.1016/j.bulcan.2016.11.021 [34] Mortazavi-jahromi S S,Aslani M,Mirshafiey A. A comprehensive review on miR-146a molecular mechanisms in a wide spectrum of immune and non-immune inflammatory diseases[J]. Immunology Letters,2020,227(1):8-27. [35] Luo X,Yang W,Ye D Q,et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus[J]. PLoS Genet,2011,7(6):e1002128. doi: 10.1371/journal.pgen.1002128 [36] Cammaerts S,Strazisar M,De rijk P,et al. Genetic variants in microRNA genes: impact on microRNA expression,function,and disease[J]. Front Genet,2015,6(1):186. [37] Hefzy E M,Hassuna N A,Shaker O G,et al. miR-155 T/A (rs767649) and miR-146a A/G (rs57095329) single nucleotide polymorphisms as risk factors for chronic hepatitis B virus infection among Egyptian patients[J]. PLoS One,2021,16(8):e0256724. doi: 10.1371/journal.pone.0256724 [38] Yu M,Al-dallal S,Al-haj L,et al. Transcriptional regulation of the proto-oncogene Zfp521 by SPI1 (PU. 1) and HOXC13[J]. Genesis,2016,54(10):519-533. doi: 10.1002/dvg.22963 [39] Tao L,Wang X,Zhou Q. Long noncoding RNA SNHG16 promotes the tumorigenicity of cervical cancer cells by recruiting transcriptional factor SPI1 to upregulate PARP9[J]. Cell Biol Int,2020,44(3):773-784. doi: 10.1002/cbin.11272 [40] Zhang J,Tan H,Cao Q,et al. Meta-analysis of miRNA variants associated with susceptibility to autoimmune disease[J]. Dis Markers,2021,2021(1):9978460. [41] Salimi S,Sargazi S,Mollashahi B,et al. Association of polymorphisms in miR146a,an inflammation-associated microRNA,with the risk of idiopathic recurrent spontaneous miscarriage: a case-control study[J]. Dis Markers,2022,2022(1):1495082.